Location History:
- Bloomington, IN (US) (2015 - 2017)
- Indianapolis, IN (US) (2020 - 2023)
Company Filing History:
4 out of 1,777 
2 out of 769 
1 out of 75 
Years Active: 2015-2023
Title: The Innovative Contributions of Brian Finan
Introduction
Brian Finan is a notable inventor based in Indianapolis, IN, who has made significant contributions to the field of pharmaceuticals. With a total of seven patents to his name, Finan's work primarily focuses on prodrugs and their applications in treating various medical conditions.
Latest Patents
Among his latest patents, Finan has developed prodrug compounds of GLP-1/GIP receptor co-agonists. These compounds are modified by linking a dipeptide to the GLP-1/GIP receptor co-agonist through an amide bond. The prodrugs he has disclosed exhibit extended half-lives and are converted to the active GLP-1/GIP receptor co-agonist under physiological conditions through a non-enzymatic reaction driven by chemical instability. Additionally, he has worked on peptide co-agonists of the human GLP-1 and GIP receptors that are suitable for oral delivery. These long-acting derivatives are intended for medical use in the treatment and prevention of obesity, diabetes, and liver diseases.
Career Highlights
Finan has had a distinguished career, working with prominent organizations such as Novo Nordisk A/S and Indiana University. His innovative research has positioned him as a key figure in the development of new therapeutic strategies.
Collaborations
Throughout his career, Finan has collaborated with esteemed colleagues, including Richard Dennis DiMarchi and Patrick J. Knerr. These partnerships have further enhanced his contributions to the field.
Conclusion
Brian Finan's work in the development of prodrugs and co-agonists has the potential to significantly impact the treatment of various health conditions. His innovative spirit and dedication to research continue to drive advancements in pharmaceutical science.